Literature DB >> 30612140

Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.

Andy Chi-Lung Lee1,2, Yu-Yin Shih3, Fanfan Zhou4, Tsi-Chian Chao3, Hsinyu Lee5,6, Yung-Feng Liao6,7, Wen-Ming Hsu8,9, Ji-Hong Hong10,11,12.   

Abstract

Oncogenic N-MYC (MYCN) is widely used as a biomarker in clinics for neuroblastoma (NB) patients; nevertheless, mechanism that underlines MYCN regulation remains elusive. In the present study, we identified calreticulin (CRT) as a novel MYCN suppressor that downregulated MYCN promoter activity and protein expression to modulate neuronal differentiation and stemness. Our data showed that CRT-mediated MYCN suppression led to increased neurite length and commensurate elevation in differentiation marker GAP-43. We examined effect of radiotherapy and discovered that ionizing radiation (IR) was able to augment CRT expression dose-dependently in NB. Interestingly, neuronal differentiation and neurosphere formation (NSF) of NB were not only co-modulated by IR and CRT but were also dependent on Ca2+-buffering domain (C-domain) of CRT. Mutagenesis analysis showed that C-domain was indispensable for CRT-mediated MYCN regulation in NB differentiation and NSF. Of note, IR-induced formation of neural stem-like neurospheres (NS) was significantly impaired in CRT-overexpressed NB cells. The occupancy of CRT on MYCN 5' proximal promoter was confirmed by chromatin immunoprecipitation assays, revealing potential CRT binding sites that coincided with transcription factor E2F1 binding elements. In addition, we identified a physical interaction between CRT and E2F1, and demonstrated that CRT occupancy on MYCN promoter prevented E2F1-mediated MYCN upregulation. In line with in vitro findings, hampered tumor latency and retarded tumor growth in xenograft model corroborated IR and CRT co-mediated neuronal differentiation of NB. Together, our data delineated a novel mechanism of CRT-mediated MYCN regulation and warranted further preclinical investigation towards new therapeutic strategy for NB. CRT suppresses MYCN expression and promotes neuronal differentiation in NB. CRT regulates MYCN via interaction with E2F1 and direct binding to MYCN promoter. Ca2+-buffering domain of CRT is critical in MYCN regulation and NB differentiation. CRT-MYCN axis impacts on NB stemness by modulating neurosphere formation. Xenograft model corroborates in vitro NB differentiation mediated by CRT and IR.

Entities:  

Keywords:  Calreticulin; Differentiation; MYCN; Neuroblastoma; Neurosphere; Radiation

Mesh:

Substances:

Year:  2019        PMID: 30612140     DOI: 10.1007/s00109-018-1730-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  49 in total

1.  Calreticulin mediates nerve growth factor-induced neuronal differentiation.

Authors:  Yu-Yin Shih; Akira Nakagawara; Hsinyu Lee; Hsueh-Fen Juan; Yung-Ming Jeng; Dong-Tsamn Lin; Yung-Li Yang; Yeou-Guang Tsay; Min-Chuan Huang; Chien-Yuan Pan; Wen-Ming Hsu; Yung-Feng Liao
Journal:  J Mol Neurosci       Date:  2011-12-07       Impact factor: 3.444

2.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.

Authors:  Jung-Hee Kang; Piotr G Rychahou; Titilope A Ishola; Jingbo Qiao; B Mark Evers; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2006-10-12       Impact factor: 3.575

4.  p53 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Lindi Chen; Nunzio Iraci; Samuele Gherardi; Laura D Gamble; Katrina M Wood; Giovanni Perini; John Lunec; Deborah A Tweddle
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

5.  E2F proteins regulate MYCN expression in neuroblastomas.

Authors:  Verena Strieder; Werner Lutz
Journal:  J Biol Chem       Date:  2002-11-15       Impact factor: 5.157

6.  Promotion of direct reprogramming by transformation-deficient Myc.

Authors:  Masato Nakagawa; Nanako Takizawa; Megumi Narita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

Review 7.  Neurotrophins and their receptors in chicken neuronal development.

Authors:  F Hallbook; A Bäckström; K Kullander; A Kylberg; R Williams; T Ebendal
Journal:  Int J Dev Biol       Date:  1995-10       Impact factor: 2.203

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

Review 9.  Promising therapeutic targets in neuroblastoma.

Authors:  Katherine K Matthay; Rani E George; Alice L Yu
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

10.  Inhibition of nuclear hormone receptor activity by calreticulin.

Authors:  S Dedhar; P S Rennie; M Shago; C Y Hagesteijn; H Yang; J Filmus; R G Hawley; N Bruchovsky; H Cheng; R J Matusik
Journal:  Nature       Date:  1994-02-03       Impact factor: 49.962

View more
  1 in total

1.  6-Hydroxydopamine Induces Neurodegeneration in Terminally Differentiated SH-SY5Y Neuroblastoma Cells via Enrichment of the Nucleosomal Degradation Pathway: a Global Proteomics Approach.

Authors:  Kasthuri Bai Magalingam; Sushela Devi Somanath; Premdass Ramdas; Nagaraja Haleagrahara; Ammu Kutty Radhakrishnan
Journal:  J Mol Neurosci       Date:  2022-03-08       Impact factor: 2.866

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.